Want to see VRDN full AI Analyst Report?
VRDN Stock Chart & Stats
$19.27
<$0.01(0.05%)
At close: 4:00 PM EDT
$19.27
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$13.18 - $34.29
Previous Close$19.2
Volume1.52M
Average Volume (3M)2.23M
Market Cap
$2.20B
Enterprise Value$1.42K
Total Cash (Recent Filing)$762.18M
Total Debt (Recent Filing)$51.17M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 12, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding110,427,680
10 Day Avg. Volume1,692,252
30 Day Avg. Volume2,232,459
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$33.91Price Target Upside75.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$21.40M
Bulls Say, Bears Say
Bulls Say
Phase 3 Success In Thyroid Eye Disease (REVEAL-2)Two successful pivotal Phase 3 data sets materially reduce clinical and regulatory execution risk for an IGF-1R therapy in TED. Meeting primary endpoints supports planned BLA timing and strengthens the company’s market positioning and commercial leverage versus competitors over the next 2–6 months.
Commercial Manufacturing Agreement With WuXi BiologicsA multi-year, non-exclusive manufacturing contract with a major CDMO materially improves launch readiness and supply scalability. Fixed service fees and rolling forecasts reduce execution and regulatory supply risk, supporting reliable commercial supply chains if approved and lowering operational uncertainty.
Significant Capital Raise Improving Liquidity And FlexibilityA sizable financing package materially extends runway to pursue regulatory filings, market expansion studies and R&D. Proceeds were allocated to repay a term loan and fund commercialization prep, reducing near-term refinancing risk and improving strategic flexibility during approval and launch phases.
Bears Say
Very High Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow at this scale creates an ongoing dependence on external financing to fund operations and commercialization. Even with recent raises, continued burn through regulatory filing and launch phases materially elevates funding and dilution risk over the coming months.
Large Recurring Net Losses And Negative MarginsVery large recurring losses limit internal capital generation and compress returns on equity, constraining reinvestment capacity. Until commercial revenue scales, negative margins will persist and may force further capital raises or cost cuts that could impact development and commercialization plans.
No Current Product Revenue; Reliance On FinancingAs a clinical-stage biotech without marketed products, Viridian must rely on capital markets for ongoing funding. That structural dependence increases execution risk and potential dilution if development timelines slip or additional commercialization investments are needed in the next several months.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $2.20B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on May 05, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.081 by $0.181.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate is -1.02.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 110,427,680 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.081. Following the earnings report the stock price went up 33.357%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.91 (75.97% Upside)
$33.91 (75.97% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.37%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is a clinical-stage biotechnology company focused on developing potential treatments for thyroid eye disease (TED) and related autoimmune conditions. The company’s pipeline includes investigational monoclonal antibody candidates designed to inhibit insulin-like growth factor-1 receptor (IGF-1R), with programs such as VRDN-001 and VRDN-003 aimed at improving outcomes and dosing convenience for patients with TED. Viridian operates in the biotechnology/pharmaceutical sector and is primarily engaged in research and development rather than commercial product sales.
VRDN Stock 12 Month Forecast
Average Price Target
$33.91
▲(75.97% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.66% Insiders
26.25% Mutual Funds
0.50% Other Institutional Investors
53.12% Public Companies and
Individual Investors